October 18, 2017 / 11:25 AM / a year ago

BRIEF-Alnylam and Vir form strategic alliance to advance RNAi therapeutics for infectious diseases

Oct 18 (Reuters) - Alnylam Pharmaceuticals Inc

* Alnylam and Vir form strategic alliance to advance RNAi therapeutics for infectious diseases

* Alnylam Pharmaceuticals Inc - ‍Agreement includes investigational RNAi therapeutic program for hepatitis B virus infection​

* Alnylam Pharmaceuticals Inc - ‍Under terms of agreement, alnylam will receive an upfront payment, comprised of cash and shares of Vir common stock​

* Alnylam - ‍Agreement includes discovery collaboration on additional development candidates for treatment of infectious diseases​

* Alnylam Pharmaceuticals - Also eligible to receive more than $1 billion in potential milestone payments related to successful advancement of ALN-HBV02​

* Alnylam Pharmaceuticals Inc - ‍As part of this agreement, companies will advance Alnylam's HBV program​

* Alnylam Pharmaceuticals Inc - Plans to discontinue further development of ALN-HBV for treatment of chronic hbv infection​

* Alnylam Pharmaceuticals Inc - ‍ Alnylam will lead ALN-HBV02 to ind filing, with vir then progressing ALN-HBV02 through human proof of concept​

* Alnylam- ‍As part of agreement, cos will advance initiate research collaboration for development, advancement of up to 4 rnai therapeutic programs​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below